凝血因子 VIII：免疫原性和免疫耐受策略的观点。
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.
机构信息
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
出版信息
Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019.
Abstract
Therapeutic treatment of bleeds with FVIII can lead to an antibody response that effectively inhibits its function. Herein, we review the factors that contribute to this immunogenicity and possible ways to overcome it.
摘要
使用 FVIII 进行治疗性止血可能会引起抗体反应，从而有效抑制其功能。在此，我们回顾了导致这种免疫原性的因素以及可能克服它的方法。
相似文献
1
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies.凝血因子 VIII：免疫原性和免疫耐受策略的观点。
Front Immunol. 2020 Jan 17;10:3078. doi: 10.3389/fimmu.2019.03078. eCollection 2019.
2
Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?治疗性因子 VIII 的致病性免疫反应：加剧的反应还是耐受诱导失败？
Haematologica. 2019 Feb;104(2):236-244. doi: 10.3324/haematol.2018.206383. Epub 2018 Dec 4.
3
Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.成年血友病A抑制物患者：使用单一FVIII/VWF产品成功诱导免疫耐受。
Haemophilia. 2014 Nov;20(6):e414-7. doi: 10.1111/hae.12521. Epub 2014 Oct 21.
4
Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.社论：耐受凝血因子VIII：预防和逆转中和性抗FVIII抗体的新策略。
Front Immunol. 2021 Jan 25;11:639386. doi: 10.3389/fimmu.2020.639386. eCollection 2020.
5
Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.一名轻度甲型血友病患者出现高滴度VIII因子抑制物的长期治疗过程。
Haemophilia. 2014 Nov;20(6):e402-4. doi: 10.1111/hae.12491.
6
To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.服务与保护：血管性血友病因子对因子 VIII 免疫原性的调节作用。
Blood Rev. 2017 Sep;31(5):339-347. doi: 10.1016/j.blre.2017.07.001. Epub 2017 Jul 4.
7
Inhibitors - cellular aspects and novel approaches for tolerance.抑制剂 - 细胞方面和新的耐受方法。
Haemophilia. 2014 May;20 Suppl 4(0 4):80-6. doi: 10.1111/hae.12407.
8
Immunological aspects of inhibitor development.抑制剂开发的免疫学方面。
Haemophilia. 2006 Dec;12 Suppl 6:30-5; discussion 35-6. doi: 10.1111/j.1365-2516.2006.01363.x.
9
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.血友病 A 和 B 的抑制剂：出血管理、抑制剂清除和治疗困难患者的策略。
Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6.
10
Summary report of the First International Conference on inhibitors in haemophilia A.第一届甲型血友病抑制剂国际会议总结报告
Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25.
引用本文的文献
1
Early postnatal expression mitigates immune responses to Cas9 in the murine central nervous system.出生后早期表达可减轻小鼠中枢神经系统对Cas9的免疫反应。
Mol Ther Methods Clin Dev. 2025 Jul 17;33(3):101536. doi: 10.1016/j.omtm.2025.101536. eCollection 2025 Sep 11.
2
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform.生物治疗药物开发过程中针对个体化缓解和监测的免疫原性风险评估：欧洲免疫原性平台的建议
Front Immunol. 2025 May 22;16:1581153. doi: 10.3389/fimmu.2025.1581153. eCollection 2025.
3
Immune tolerance promotion by LSEC-specific lentiviral vector-mediated expression of the transgene regulated by the stabilin-2 promoter.通过稳定素-2启动子调控的转基因在肝窦内皮细胞特异性慢病毒载体介导下表达来促进免疫耐受。
Mol Ther Nucleic Acids. 2024 Jan 17;35(1):102116. doi: 10.1016/j.omtn.2024.102116. eCollection 2024 Mar 12.
4
Immunogenic epitope scanning in bacteriolytic enzymes Pal and Cpl-1 and engineering Pal to escape antibody responses.免疫原性表位扫描在溶菌酶 Pal 和 Cpl-1 中，并对 Pal 进行工程改造以逃避抗体反应。
Front Immunol. 2023 Sep 15;14:1075774. doi: 10.3389/fimmu.2023.1075774. eCollection 2023.
5
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications.血友病 A 患者伴抑制物：作用机制的新见解及新的治疗意义。
Front Immunol. 2022 Dec 8;13:1019275. doi: 10.3389/fimmu.2022.1019275. eCollection 2022.
6
Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: Impact of excipients.治疗性肽和蛋白质中先天免疫反应调节杂质（IIRMI）的检测：赋形剂的影响。
Front Immunol. 2022 Sep 6;13:970499. doi: 10.3389/fimmu.2022.970499. eCollection 2022.
7
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.获得性血友病 A 中自身抗体的靶标不仅限于因子 VIII：来自 GTH-AH 01/2010 研究的数据。
Blood Adv. 2023 Jan 10;7(1):122-130. doi: 10.1182/bloodadvances.2022008071.
8
Nonhuman sugars cause factor VIII troubles.非人类糖类会引发凝血因子VIII问题。
Blood. 2022 Mar 3;139(9):1262-1263. doi: 10.1182/blood.2021012121.
9
Protein residue network analysis reveals fundamental properties of the human coagulation factor VIII.蛋白质残基网络分析揭示了人类凝血因子 VIII 的基本特性。
Sci Rep. 2021 Jun 16;11(1):12625. doi: 10.1038/s41598-021-92201-3.
10
Nonhuman glycans can regulate anti-factor VIII antibody formation in mice.非人类聚糖可调节小鼠抗因子 VIII 抗体的形成。
Blood. 2022 Mar 3;139(9):1312-1317. doi: 10.1182/blood.2020009210.
本文引用的文献
1
Tolerating Factor VIII: Recent Progress.耐受因子 VIII：最新进展。
Front Immunol. 2020 Jan 10;10:2991. doi: 10.3389/fimmu.2019.02991. eCollection 2019.
2
Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.因子 VIII 特异性调节性 T 细胞的抗原特异性体外扩增可诱导血友病 A 小鼠产生耐受性。
J Thromb Haemost. 2020 Feb;18(2):328-340. doi: 10.1111/jth.14659. Epub 2019 Oct 29.
3
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.通过改造因子 VIIa 类似物来减轻 T 细胞依赖性免疫原性。
Blood Adv. 2019 Sep 10;3(17):2668-2678. doi: 10.1182/bloodadvances.2019000338.
4
The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors.因子 VIIa 在血友病伴抑制物患者出血治疗中的演变。
Haemophilia. 2019 Nov;25(6):911-918. doi: 10.1111/hae.13845. Epub 2019 Sep 5.
5
Engineered ovalbumin-expressing regulatory T cells protect against anaphylaxis in ovalbumin-sensitized mice.工程化表达卵清蛋白的调节性 T 细胞可预防卵清蛋白致敏小鼠的过敏反应。
Clin Immunol. 2019 Oct;207:49-54. doi: 10.1016/j.clim.2019.07.009. Epub 2019 Jul 17.
6
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.内源性血管性血友病因子的凝血因子VIII结合能力在重度甲型血友病患者凝血因子VIII抑制剂形成中的作用
Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31.
7
The future of bypassing agents for hemophilia with inhibitors in the era of novel agents.新型药物时代，针对血友病伴抑制剂患者旁路制剂的未来。
J Thromb Haemost. 2018 Dec;16(12):2362-2374. doi: 10.1111/jth.14296. Epub 2018 Oct 11.
8
Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.工程化表达 FVIII 的细胞毒性 T 细胞在体外和体内靶向并杀伤 FVIII 特异性 B 细胞。
Blood Adv. 2018 Sep 25;2(18):2332-2340. doi: 10.1182/bloodadvances.2018018556.
9
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins.降低重组免疫毒素免疫原性的策略。
Am J Pathol. 2018 Aug;188(8):1736-1743. doi: 10.1016/j.ajpath.2018.04.016. Epub 2018 Jun 2.
10
Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.工程化的 MBP 特异性人 Tregs 通过 IL-2 触发的效应 T 细胞抑制改善 MOG 诱导的 EAE。
J Autoimmun. 2018 Aug;92:77-86. doi: 10.1016/j.jaut.2018.05.003. Epub 2018 May 30.
Zotero 插件